Shanghai Vitalgen Biopharma Co., Ltd.

This early-stage study is testing whether a new gene therapy called VGR-R01 is safe for people with Bietti Crystalline Dystrophy, a rare genetic eye disease that causes vision loss. The trial will enroll 12 adults to receive a single injection into the eye and monitor them closel…

This study is testing whether a one-time gene therapy injection called VGR-R01 can slow or stop vision loss in adults with Bietti Crystalline Dystrophy, a rare inherited retinal disease. It will enroll 45 participants, with two-thirds receiving the therapy in one eye and the rest…